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1. Introduction 
For centuries, the pharmaceutical profession has provided services of fundamental value to 
society, such as the procurement, storage, compounding and dispensing of drugs. In recent 
decades, the focus of the pharmacist’s role has shifted from compounding medicines to 
ensuring their safe and effective use by providing information and advice [1,2]. Although 
compounding activity has decreased over time, it is incontestable that this service is 
essential in certain patient specific situations, where industrially produced medicine is not 
available or is inappropriate for a particular reason [3,4]. Thus, compounded medicines are 
mainly important for paediatric and geriatric patients, and patients with special needs such 
as those with dermatological diseases [3,5,6,7,8]. In many countries, nowadays, the activity 
of compounding is a complementary practice to the production of medicines in alternative 
amounts and diversified dosage forms (liquid, semi-solid, solid) in community pharmacies 
(United States of America, The Netherlands), as well as in hospital pharmacies (Canada, 
France, Belgium, Croatia, Denmark, England, Finland, Germany, Ireland, Italy, Norway, 
Scotland, Slovenia, Spain, Sweden, Switzerland) [3,4,8-10]. 
Interestingly, compounded medicines were estimated to make up 10-15% of all dispensed 
drugs in the Netherlands in the early 90’s, 5.5% in 1994 and 6.6% in 1995. By the year 2000 
this estimate was 3.7-5.5% [3]. On the other hand, the compounding field appears to have 
been a considerable and growing business since the 1990’s in the United States. These 
products represented around 1% of all prescriptions dispensed yearly and according to this 
estimate, 30 million medications would have been compounded in 2003 [4]. This shows that 
the population has recognized that compounding pharmacies can provide individualized 
drug therapy benefits [11]. 
The practice of compounding requires not only the drug(s) (active pharmaceutical 
ingredient, API), but also, the excipient(s) (pharmacological inert component) in order to 
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obtain the final medicine. The excipients are chosen according to the characteristics of the 
required dosage form [5]. Each excipient exerts specific functions in the formulation, as, for 
instance, a diluent for hard capsules or powders, a coating agent for solid oral dosage forms, 
a suspending, thickening or stabilizing agent for oral liquids, etc. The excipient function 
depends on the concentration in a particular pharmaceutical formulation [12,13]. 
Cellulose (Figure 1) and its derivatives (ether and ester) are among the excipients frequently 
used in pharmaceutical compounded and industrialized products with various purposes. 
Among their uses, the most frequently reported are as suspending agents in oral liquid 
extemporaneous preparation and as viscosity increasing agents in topical formulations, 
exemplified in Tables 1, 2 [5,7,8,14]. Particularly, in oral solid dosage forms, cellulose and its 
derivatives (also known as cellulosics) can render distinct drug delivery property patterns: 
immediate, controlled/sustained or delayed release [15,16]. In addition, cellulosics show 
several interesting characteristics such as low cost, reproducibility, biocompatibility, and 
recyclability [16]. The latter is currently an important aspect considering the need for green 
technology. 
 
Figure 1. The chemical structure of cellulose with two β-1,4 linked anhydroglucose units. 
Cellulose is the most abundant biopolymer. It is present in the cell walls of a great diversity 
of organisms, from bacteria (Cyanobacteria), prokaryotes (Acetobacter, Rhizobium, 
Agrobacterium) to eukaryotes (fungis, amoebae, green algae, freshwater and marine algae, 
mosses, ferns, angiosperms, gymnosperms). It is also produced by some animals, the 
tunicates (urochordates), members of the subphylum Tunicata in the Chordata phylum [17-
19]. Native cellulose made by biosynthesis in living organisms is composed only of glucose 
monomers, as anhydroglucose (AGU) or glucan units (C6H10O5, n) with -1,4 linkages 
(Figure 1). It usually exists as cellulose I (in most plants) and rarely as cellulose II (in several 
algae and some bacteria) allomorphs, in which the glucan chains are oriented parallel and 
antiparallel respectively [20, 21]. Cellulose allomorphs (I, II, IIII, IIIII, IVI, IVII) have structural 
variations regarding unit cell dimensions, degree of intra/interchain hydrogen bonding per 
unit cell and polarity of adjacent cellulose sheets [22]. Cellulose I allomorphs consist of 
distinct numbers of parallel glucan chains arranged to form nanofibrils. Native crystalline 
cellulose I has two suballomorphs,  and , which exist as a single chain triclinic unit cell 
and a two chain monoclinic unit cell, respectively. Cellulose I  is rarely synthesized in 
nature as a pure form (except by tunicates) and is more thermodynamically stable [20]. 
Cellulose I can be altered by a strong alkali treatment in order to produce other crystalline 
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forms, II, III and IV. Cellulose II is the allomorph that is thermodynamically most stable 
[16,23-24]. Cellulose III can be prepared by liquid ammonia or (mono, di, tri) amine 
treatment of cellulose I and II [25]. The cellulose IV crystalline form is obtained by 
immersion in glycerol and heating of cellulose III [26]. Cellulose is an excipient widely 
employed by both pharmaceutical companies (tablet processing) and compounding 
pharmacies; it is available in powdered (n500) and microcrystalline (n220) forms, the 
latter being obtained by acid hydrolysis of the amorphous regions of the cellulose 
nanofibrils. 
Cellulosics, such as methyl, ethyl, hydroxyethyl, hydroxyethylmethyl, hydroxypropyl (HP), 
hydroxypropyl methyl (HPM, also denominated hypromellose) and carboxymethyl ethers 
cellulose (Figure 2) are formed by hydroxyl etherification with the appropriate alkyl halide 
(R-Cl, see Figures 2, 3) from previously alkalinized cellulose usually obtained from wood 
pulp [16]. The degree of substitution (DS) in these ether derivatives indicates the average 
number of R groups present in each glucan unit along the chain. The maximum DS is three, 
since it is the number of hydroxyl groups that can be substituted on each glucan unit. DS 
affects cellulose derivatives’ physical properties such as solubility [12]. 
 
Figure 2. Chemical structure of cellulose ether derivatives. 
Cellulose derivatives are employed as excipients in pharmaceutical industrial products for 
oral, topical or parenteral administration [12,16,27]. Their most relevant application, as 
observed in pharmaceutical industrial products, is to create matrix systems for solid oral 
dosage forms. Due to their aqueous swelling, the drug release is controlled by its diffusion 
through the hydrogel layers that are formed. For instance, the use of carboxymethyl 
cellulose (CMC) sodium salt as an excipient sustains the release in solid oral dosage forms. 
Cellulosics, such as the cellulose esters acetate, acetate trimellitate, acetate phthalate (CAP), 
HPM phthalate, HPM acetate succinate are formed by hydroxyl esterification with either 
acetic, trimellitic, dicarboxylic phthalic or succinic acids, or a combination of them, as 
represented in Figure 3. The reaction usually occurs in the presence of a strong acid that 
promotes the acid catalysis.  
Among these cellulosics, CAP was one of the earliest and most effective solutions to pH-
controlled release, and its use still continues today [15]. These cellulosics are usually 
resistant to acid environments such as that of the stomach and are thus very useful as enteric 
coatings for capsules or tablets [12,16]. Cellulose esters require plasticizers (acetylated 
monoglyceride, butyl phtalylbutyl glycolate, dibutyl tartrate, diethyl phthalate, dimethyl 
phthalate, ethyl phthalylethyl glycolate, glycerin, propylene glycol, triacetin, triacetin 
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citrate, triethylcitrate, tripropionin) soluble in organic solvents (ketones, esters, ether 
alcohols, cyclic ethers) or in their mixtures, such as methanol/chloroform and ethyl 
acetate/isopropanol in order to produce more effective coating films [12,28,29]. Some of the 
cellulose esters are employed either in industrial or compounded pharmaceutical 
preparations. 
Some cellulosics, if they are to be applied in distinct drug delivery formulations, may 
require special large scale processing and equipment normally only installed in 
pharmaceutical industry plants. This is one of the reasons why not all commercially 
available cellulosics are employed in compounding pharmacies. A description of some 
cellulosics and their applications in compounded medicines is presented in the following 
sections. 
 
Figure 3. Chemical structures of cellulose ester derivatives. 
2. Cellulose and its derivatives in compounded medicines 
2.1. Cellulose 
Powdered cellulose and microcrystalline cellulose come from -cellulose (cellulose free of 
hemi-celluloses and lignin) pulp from fibrous plant materials; they differ in regard to their 
manufacturing processes. Powdered cellulose is obtained by -cellulose purification and 
mechanical size reduction. Crystalline cellulose is obtained by controlled hydrolysis of -
cellulose with mineral acid solutions (2 to 2.5 N), followed by hydrocellulose purification by 
filtration and spray-drying of the aqueous portion [12]. 
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In compounded medicines, powdered cellulose and microcrystalline cellulose are used as an 
adsorbent, a suspending agent, a capsule diluent (5-30% and 20-90%, respectively). 
Powdered cellulose is also used as a thickening agent. 
The applications of the powdered cellulose and the microcrystalline cellulose in compounding 
pharmacies include the oral solid dosage form (capsules) as a bulking agent to increase the 
mass in formulations containing small amounts of the active ingredient. The powdered 
cellulose is a base material for powder dosage forms, a suspending agent for aqueous peroral 
delivery and an adsorbent and thickening agent for topic preparations [12]. Moreover, the 
microcrystalline cellulose is a constituent of the vehicle used for oral suspension [27]. 
2.2. Cellulose ether derivatives 
2.2.1. Methylcellulose (MC) 
In this cellulose ether derivative approximately 27–32% of hydroxyl groups are changed to 
the methyl ether (CH3O) form. MC is practically insoluble in most organic solvents. Various 
grades of MC can be found with degrees of polymerization in the range of 50 to 1000 and 
molecular weights (number average) in the range 10 000 to 220 000 Da [12]. 
In compounded medicines, MCs function as emulsifying agents (1-5%), suspending agents 
(1-2%), capsule disintegrants and viscosity increasing agents.  
In compounding pharmacies, MCs of different viscosity grades, low and high, have been 
applied in oral liquid (oil emulsions, suspensions, solutions) and topical (creams, gels) 
formulations respectively. MC is often used instead of sugar-based syrups and other 
suspension bases. MC delays the settling of suspensions and increases the contact time of 
drugs in the stomach [12]. 
2.2.2. Ethylcellulose (EC) 
This cellulose derivative is partially or completely ethoxylated, yielding 44-51% of ethoxyl 
groups (OCH2CH3). Full substitution (DS=3) of cellulose units produce 
C12H23O6(C12H22O5)nC12H23O5, where n can vary, thus providing a wide variety of molecular 
weights. EC is a long-chain polymer of ethyl-substituted -glucan units joined together by 
glycoside linkages [12]. 
In compounded medicines, EC functions as a flavouring and as a viscosity increasing agent. 
In compounding pharmacies, EC finds applications in oral and topical (creams, lotions, gels) 
formulations. For oral use, it works as an active delivering agent and for topical dosage 
forms as a thickening agent. It has been evaluated as a stabilizer for emulsions [12]. 
2.2.3. Hydroxyethylcellulose (HEC) 
This cellulose derivative is a partially substituted hydroxyethyl (CH2CH2OH) ether of 
cellulose. It is found in various viscosity grades, with respect to the DS and molecular 
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weight. Some grades are modified so as to improve aqueous dispersion. HEC is insoluble in 
most organic solvents. 
In compounded medicines, HEC has the following functions: a suspending, a thickening 
and a viscosity-increasing agent. 
It is widely employed in topical formulations (gel) and cosmetics due to its nonionic and 
water-soluble polymer characteristics. The main use is as a thickening agent [12]. 
2.2.4. Hydroxypropylcellulose (HPC) 
This cellulose derivative is partially hydroxypropylated, yielding 53.4–80.5% of 
hydroxypropyl groups [OCH2CH(OH)CH3]. Because the added hydroxypropyl contains a 
hydroxyl group which can also be etherified during the preparation, the degree of 
substitution of hydroxypropyl groups can be higher than three. HPC is found in different 
grades that provide solutions with various viscosities. Its molecular weight has a range of 50 
000 to 1 250 000. HPC with an value of moles of substitution of approximately four is 
necessary in order to have good water solubility. 
In compounded medicines, HPC is used as an emulsifying, a stabilizing, a suspending, a 
thickening or a viscosity-increasing agent. 
In compounding pharmacies, HPC is also employed in topical formulations (gel) and 
especially in cosmetics, as an emulsifier and a stabilizer [12]. 
2.2.5. Hydroxypropylmethylcellulose (HPMC) 
This cellulose derivative, also called  hypromellose, is a partly O-methylated and O-(2-
hydroxypropylated) cellulose. HPMC is found in various grades with different viscosities 
and extents of substitution. The content of methoxyl (OCH3) and hydroxypropyl groups 
[OCH2CH(OH)CH3] affects the HPMC molecular weight, which ranges from 10 000 to  
1 500 000. 
HPMC has many different functions in compounded medicines as a dispersing, an 
emulsifying, a foaming, a solubilizing, a stabilizing, a suspending (0.25-5%) and a thickening 
(0.25-5%) agent. In addition, HPMC can be applied as a controlled-release and sustained-
release agent. 
In compounding pharmacies, HPMC has found application for nasal (liquid) and topical 
(gel, ointment) formulations as a thickening, a suspending, an emulsifying and a stabilizing 
agent. The aqueous solution produced with HPMC presents greater clarity and fewer 
undissolved fibres compared with MC. HPMC can prevent droplets and particles from 
coalescing or agglomerating, thus inhibiting the formation of sediment. In addition, it is also 
widely used in cosmetics [12]. 
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2.2.6. Carboxymethyl cellulose (CMC) 
It is available as calcium and sodium salt forms of a polycarboxymethyl (CH2COOX, X=Ca 
or Na) ether of cellulose. Only sodium CMC is commonly used in compounded 
preparations. The degree of substitution can be estimated by a sodium assay, which must be 
between 6.5-9.5%. 
CMC-Na acts as a capsule disintegrant and a stabilizing, a suspending, an emulsifying (0.25-
1%), a gel-forming (3-6%) and a viscosity-increasing (0.1-1%) agent in compounded medicines. 
In compounding pharmacies, CMC-Na has applications in oral (liquid, solid) and topical 
(liquid, gel, emulsion) formulations, primarily for its viscosity-increasing properties. 
Viscous aqueous solutions are used to suspend powders intended for either topical or oral 
use. In emulsions, CMC may be used as stabilizer. At higher concentrations, a CMC of 
intermediate-viscosity grade forms gels that are employed as a base for cosmetics or other 
drug formulations [12]. Similarly to microcrystalline cellulose, CMC-Na is also described as 
a constituent of vehicles used for oral suspension [27]. 
2.3. Cellulose ester derivatives 
2.3.1. Cellulose acetate 
This cellulose derivative has partially or completely acetylated (COCH3) hydroxyl groups. 
Cellulose acetate is available in a wide range of acetyl levels (29-44.8%) and chain lengths, 
with molecular weights ranging from 30 000 to 60 000. 
Cellulose acetate is used as a capsule diluent, a filler and as a taste-masking agent in 
compounded medicines [12]. 
2.3.2. Cellulose acetate phthalate (CAP) 
CAP acid form is a cellulose derivative obtained by the reaction of phthalic anhydride and a 
partial acetate ester of cellulose. It contains 21.5–26% of acetyl (COCH3) and 30-36% of 
phthalyl (o-carboxybenzoyl, COC6H4COOH) groups. 
In compounded medicines, CAP confers gastro-resistance, and is thus used as an enteric 
coating agent (0.5-9%) [12]. 
In compounding pharmacies, CAP has applications in oral solid dosage forms either by film 
coating from organic (ketones, esters, ether alcohols, cyclic ethers) or aqueous solvent 
systems. Such coatings resist prolonged contact with the strongly acidic gastric fluid, but 
dissolve in the mildly acidic or neutral intestinal environment. The addition of plasticizers 
improves the water resistance of such coating materials, making formulations with this 
derivative more effective [12,29]. 
As mentioned, cellulose and its derivatives, primarily intended for use in the 
pharmaceutical industry, are also relevant in compounding practice. The common uses of 
cellulosics in compounding practices as a diluent in solid dosage forms, a thickening and a 
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suspending agent in liquid dosage forms, an emulsifying agent in semi-solid preparations 
and others require well known manufacturing techniques, which do not need sophisticated 
apparatus [5]. Nevertheless, specific equipment may be necessary when cellulosics are 
employed to impart special dosage form properties, such as in modified release systems. 
Among the modified drug delivery systems, mostly delayed and controlled (extended or 
slow) release have been described in compounding practice. In the former, the systems are 
frequently employed to prevent drug degradation in acid environments after oral 
administration, to protect the stomach mucosa from drug irritation and to release the drug 
in the intestine. In controlled release, systems are used to prevent side effects and to reduce 
the number of daily administrations [29,30]. 
CAP is the cellulosic most frequently mentioned in compounded delayed-release dosage 
forms [31-33]. The use of sodium carboxymethylcellulose or hydroxypropyl methylcellulose 
have also been reported in extended or slow-release systems [34-40]. These systems are most 
commonly obtained by the simple mixing of the drug with an appropriate inert matrix [39]. 
The Food and Drug Administration (FDA) warns that in some instances, compounders may 
lack sufficient control techniques and resources (equipment, training, testing or facilities) to 
assure product quality or to compound more elaborated products such as modified release 
drugs [4]. Since obtaining high quality, safe and effective products is fundamental, 
compounding techniques must be developed and standardized. Thus, coating techniques 
used to obtain delayed release compounded capsules by the beaker flask method, by 
dipping or by spraying have been proposed [41]. In beaker flask coating, a small amount of 
coating material is added to the beaker and heated until melted. Subsequently, a few 
capsules are added away from the heat and the beaker is manually rotated to coat them. 
Small quantities of coating material are continuously added in order to prevent the capsules 
from sticking. The immersion or dipping method consists of heating the coating material in 
a recipient that permits the dipping of the capsules with the aid of tweezers in the coating 
solution and subsequent hardening. This process is repeated until all the capsules have a 
homogenous film. The vaporization or atomization method, also called spraying, consists in 
preparing a solution of the coating material in alcohol, ether, or keto-alcoholic solvents and 
transferring it to a spray bottle. The capsules are held over a screen, under ventilation. The 
coating solution is applied in multiple thin layers that are allowed to dry between 
applications. A small scale piece of machinery exists for this coating process [33]. 
3. Review of the use of cellulosics in compounding 
The use of cellulose and/or its derivatives as part of compounded formulations has been 
cited in a great number of studies in the literature. A review of their properties and usage in 
pharmaceutical preparations is presented in the following section. Focus is given to the 
products that require more elaborate techniques in compounding pharmacies. 
3.1. Cellulose derivatives in oral liquid (suspensions) extemporaneous preparation 
It is well known that children and the elderly have difficulties in swallowing solid dosage 
forms, due to their size or texture. Such population groups benefit from oral liquid 
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administration; hence, this is a preferred means of administration. Frequently, drugs in a 
concentration appropriate for paediatric use are unavailable or extemporaneous 
preparations from commercial products become a necessity. Thus, patients with special 
needs can be provided with drugs easily administered in the hospitals if extemporaneous 
preparations are compounded from drugs that are industrially produced. 
Methylcellulose (1%) and simple syrup NF (as described in the United States Pharmacopeia 
National Formulary monograph) mixtures have been used as a vehicle for many 
extemporaneous oral drug suspensions prepared from commercial products (tablets or 
capsules) [27,41]. Compounded oral preparations can be obtained by finely grinding tablets 
or the content of capsules in a mortar and pestle, with the gradual addition of small volumes 
of the vehicle being mixed. The final volume can be adjusted in a graduated glass cylinder. 
Afterwards, the suspension is transferred to an appropriate plastic or glass bottle protected 
(amber) or not (transparent) from light. 
Stability studies conducted at 4 °C and 25 °C for distinct drugs over at least 8 weeks are 
shown in Table 1 [42-52]. 
In such listed studies, suspensions containing MC did not show substantial changes in pH, 
odour or physical appearance in the period during which the drug content was assayed and 
found not to be less than 90% of the original concentration. This is a demonstration that MC 
formulations provide satisfactorily safe and stable products. 
Oral extemporaneous suspensions of other drugs (amiodarone, granisetron, trimethoprim, 
and verapamil salt) prepared in methylcellulose and simple syrup (MC:SS) were also 
reported to have adequate stability [14]. 
 
Drug [Ref.] 
Drug dosage form
(mg) 
Suspension
(mg/mL) 
MC:SS
ratio 
Stability (days) 
in different 
temperatures 
    4 C 25 C 
Clonazepam [42] Tablets (0.5, 1, 2) 0.1 NI 60c NE 
Gabapentin [43] Capsules 
(100, 300, 400) 
100 1:1 91c 56c 
Nifedipine [44] Capsules (10, 20) 4 1:13 91b 91b 
Procainamide hydrochloride 
[45] 
Capsules, tablets 
(250, 375, 500) 
5, 50 
70:30 Cherry 
syrup 
180b 180b 
Propylthiouracil [46] Tablets (50) 5 1:1 91c 70c 
Pyrazinamide [47] Tablets (500) 100 1:1 60b 60b 
Pyrimethamine [48] Tablets (25) 2 1:1 91a,c 91a,c 
Sildenafil citrate [49] Tablets (25, 50, 100) 2.5 1:1 91c 91c 
Sotalol hydrochloride 
[50,51] 
Tablets (80, 120, 160, 240) 
5 1:9 91b 91b 
 2.4:1 84a 84a 
Tiagabine hydrochloride [52] Tablets (2, 4, 6, 8, 10, 12, 16) 1 1:6 91c 42c 
a: amber glass, b: plastic; c: amber plastic bottles; NI, not informed; NE, not evaluated. 
Table 1. Stability of different drugs in oral suspension extemporaneously prepared in a mixture of 1% 
methylcellulose:simple syrup (MC:SS) from commercial available products. 
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Another cellulose derivative frequently used as part of a vehicle in oral extemporaneous 
suspensions is sodium carboxymethylcellulose. It is a constituent of a commercial product, 
Ora-Plus®, which is employed in a 1:1 mixture with Ora-Sweet® (with sugar) or Ora-Sweet 
SF® (sugar free) [7,8]. Ora-Sweet® is a sugar-based citrus-berry flavoured syrup (see Table 2 
footnote). Researchers have performed stability studies for various oral suspensions of 
drugs with this vehicle. The results of drug stability tests for periods of at least 8 weeks at 
refrigerated (3-5°C) and room (22-25°C) temperatures, are presented in Table 2 [43,46,49-77]. 
 
Drug [Ref.] 
Dosage form
(mg) 
Suspension
(mg/mL) 
CMC or Ora-
Plus added (1:1) 
of 
Stability (days) in 
different 
temperatures 
    3-5°C 22-25°C 
Acetazolamide [53,54] Tablets 
(125, 250) 
25a 
Ora-Sweet® 
Ora-Sweet SF® 
60g 60g 
Allopurinol [54] Tablets 
(100, 300) 
20a 
Alprazolam [55] Tablets (0.25, 0.5, 1, 2) 1a 
Ora-Sweet® 
Ora-Sweet SF® 
60h 60h 
Azathioprine [54] Tablets (50) 50a 60g 60g 
Baclofen [56] Tablets (10, 20) 10a 
60h 60h Bethanechol chloride 
[57] 
Tablets 
(5, 10, 25, 50) 
5a 
Captopril [56] Tablets (12.5, 25, 50, 100) 0.75a <10h <10h 
Chloroquine phosphate 
[55] 
Tablets 
(250, 500) 
15a 
60h 60h 
Cisapride [55] Tablets (10, 20) 1a 
Clonazepam [54] Tablets 
(0.5, 1, 2) 
0.1a 60g 60g 
Dapsone [58] Tablets 
(25, 100) 
2 Ora-Sweet® 91e 91e 
Diltiazem HCl [56] Tablets (30, 60, 90, 120) 12a 
Ora-Sweet® 
Ora-Sweet SF® 
60h 60h Dipyridamole [56] Tablets 
(25, 50, 75) 
10a 
Dolasetron mesylate [59]
Tablets 
(50, 100) 
10 
Strawberry 
syrup Ora-
Sweet SF® 
90e 90e 
Enalapril maleate [55] 
Tablets (2.5, 5, 10, 20) 1a 
Ora-Sweet® 
Ora-Sweet SF® 
60h 60h 
Famotidine [60] Tablets 
(10, 20, 40) 
8 Ora-Sweet® NE 95h 
Flecainide acetate [56] Tablets 
(50, 100, 150) 
20a 
Ora-Sweet® 
Ora-Sweet SF® 
60h 60h 
Flucytosine [54] Tablets 
(250, 500) 
10a 60g 60g 
Gabapentin [43] Capsules (100, 300, 400) 100 Ora-Sweet® 91e 56e 
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Drug [Ref.] 
Dosage form
(mg) 
Suspension
(mg/mL) 
CMC or Ora-
Plus added (1:1) 
of 
Stability (days) in 
different 
temperatures 
    3-5°C 22-25°C 
Hydralazine HCl [55] 
Tablets (10, 25, 50, 100) 4a 
Ora-Sweet® 
Ora-Sweet SF® 
1h unstable
h 2h 
Ketoconazole [61] Tablets (200) 20a 
60h 60h 
Labetalol HCl [62] Tablets (100, 200, 300) 40a 
Lamotrigine [63] Tablets (25, 100, 150, 
200) 
1 91h 91h 
Levodopa + carbidopa 
[64] 
Tablets 
(100+25) 
5 
2.5 
Ora-Sweet® 42e 28e 
Levofloxacin [65] 
Tablets (200, 500, 750) 50 
Strawberry 
syrup 
57e 57e 
Metolazone [61] Tablets 
(2.5, 5, 10) 
1a 
Ora-Sweet® 
Ora-Sweet SF® 
60h 60h 
Metoprolol tartrate [62] Tablets 
(50, 100) 
10a 
90e 90e 
Moxifloxacin [66] Tablets (400) 20 
Mycophenolate mofetil 
[67] 
Capsules (250) 
Tablets (500) 
50, 100 Ora-Sweet® 91d 91d 
Naratriptan HCl [68] 
Tablets (1, 2.5) 0.5 
Ora-Sweet® 
Ora-Sweet SF® 
90e 7e 
Nifedipine [44] Capsules 
(10, 20) 
4 Ora-Sweet® 91d 91d 
Norfloxacin [69] 
Tablets (400) 20b 
Strawberry 
syrup 
56d 56d 
Procainamide HCl 
[45,61] 
Capsule/tablets 
(250, 375, 500) 
50a 
Ora-Sweet® 
Ora-Sweet SF® 
60h 60h 
Propylthiouracil [46] Tablets (50) 5 91e 70e 
Pyrazinamide [57] Tablets (500) 10a 
60h 60h Quinidine sulphate [57] Tablets 
(200, 300) 
10a 
Rifabutin [70] Capsules (150) 20 Ora-Sweet® 84g 84g 
Rifampin [57] Capsules 
(150, 300) 
25a 
Ora-Sweet® 
Ora-Sweet SF® 
28h 28h 
Sildenafil citrate [49] Tablets 
(25, 50, 100) 
2.5 Ora-Sweet® 91e 91e 
Sotalol HCl [50,51] Tablets (80, 120, 160, 
240) 
5 
Ora-Sweet® 91d, 84c 
Ora-Sweet SF® 84c 
Spironolactone [61,71] 
Tablets 
(25, 50, 100) 
1 Simple syrup 91c 91c 
2.5a 
Ora-Sweet® 
Ora-Sweet SF® 
60h 60h 
Spironolactone + 
hydrochlorothiazide [62]
Tablets 
(25+25) 
(5+5)a 
Ora-Sweet® 
Ora-Sweet SF® 
60h 60h 
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Drug [Ref.] 
Dosage form
(mg) 
Suspension
(mg/mL) 
CMC or Ora-
Plus added (1:1) 
of 
Stability (days) in 
different 
temperatures 
    3-5°C 22-25°C 
Sunitinib malate [72] Capsules (50) 10 Ora-Sweet® 60c 60c 
Tacrolimus [73-75] Capsules 
(0.5, 1, 5) 
0.5 
Simple syrup 
NF 
NE 56c,e 
Terbinafine HCl [76] Tablets (250) 25 Ora-Sweet® 42h 42i 
Tetracycline HCl [57] Capsules 
(250, 500) 
25a 
Ora-Sweet® 
Ora-Sweet SF® 
28g 28h 
10g 7h 
Theophylline [77] 
Capsules (125, 200, 300) 5 
Ora-Sweet® 
Ora-Sweet SF® 
NE 90e 
Tiagabine HCl [52] Tables (2, 4, 6, 8, 10, 12, 
16) 
1 Ora-Sweet® 91d 70e 
a: storage in the dark, b: at fluorescent lighting, c: amber glass, d: plastic, e: amber plastic, f: polyvinyl chloride, g: 
polyethylene terephthalate (PET), h: amber PET; i: amber high density polyethylene bottles; NE, not evaluated; HCl, 
hydrochloride.  
Ora-Plus® constituents: CMC-Na, citric acid, flavouring, methylparaben, microcrystalline glucose, potassium sorbate, 
purified water, simethicone, sodium phosphate, xanthan gum, pH 4.2. Ora-Sweet® constituents: citric acid, 
flavouring, glycerin, methylparaben, purified water, sodium phosphate, sorbitol, sucrose, potassium sorbate, pH 4.2. 
Ora-Sweet SF® constituents: citric acid, flavouring, glycerin, methylparaben, propylparaben, potassium sorbate, 
purified water, sodium saccharin, sodium citrate, sorbitol, xanthan gum, pH 4.2. Sugar-free.
Table 2. Stability of different drugs in oral suspension extemporaneously prepared from commercially 
available sodium carboxymethylcellulose (CMC-Na) in Ora-Plus® and/or other vehicle constituents. 
Most of the suspensions prepared presented no substantial changes in pH, odour or 
physical appearance, showing that CMC-Na base usually provides products with a 
satisfactory safety and stability (drug content equal or superior to 90% of the original 
concentration) over a period of 8 weeks. 
The use of Ora-Plus® extemporaneous oral suspension has provided satisfactory stability 
for aminophylline, cyclophosphamide, domperidone, granisetron, itraconazole, ursodiol 
and tramadol hydrochloride associated with acetaminophen [14,78]. However, for captopril, 
hydralazine hydrochloride and tetracycline hydrochloride, the suspensions were reported 
as not having enough stability. The problem of stability with captopril is due to its oxidative 
degradation, which can be solved by the addition of EDTA disodium [79]. Although, these 
studies are important, most of them have not evaluated the microbiological stability, an 
essential criterion for liquid dosage forms. 
In addition to MC and CMC-Na, HPMC has also been employed in extemporaneous oral 
suspension. For instance, nifedipine tablets or drug powder, prepared with HPMC 1% 
solution in order to obtain a suspension of 1 mg/mL concentration, was stable for at least 4 
weeks when stored at room or refrigerated temperatures and protected from light [80]. 
There is no doubt that these drug stability results are important for providing formulations 
for both paediatric patients and the geriatric populations that have difficulty in swallowing 
capsules or tablets. 
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3.2. Cellulose and its derivatives in oral solid dosage forms 
3.2.1. Mycrocrystalline cellulose in immediate release 
Microcrystalline cellulose is reported as an excipient (diluent) in oral powder and capsules 
extemporaneously compounded for paediatric use. Capsules and powders were prepared 
from commercial tablets containing 10 mg of nifedipine, which was mixed with different 
amounts of lactose or microcrystalline cellulose in a mortar with pestle using standard 
geometric dilution. Capsules were filled by a hand-operated capsule-filling machine. The 
oral powders and capsules containing extemporaneously prepared nifedipine showed 
acceptable quality regarding content uniformity, but considerable loss of the active 
ingredient occurred during the compounding process for both preparations. The authors 
demonstrated that oral powders of nifedipine (a light sensitive drug) can be replaced by 
capsules, which were adequately safe with either lactose monohydrate or microcrystalline 
cellulose as excipients for delivering a paediatric medication [81]. 
Recently, microcrystalline cellulose and two other common pharmaceutical excipients 
(starch and lactose) were investigated with regards to the choice of the best diluent for 
Gymnema sylvestre extract (a plant used as an adjuvant in the treatment of diabetes mainly in 
China) used to compound capsules. The Gymnema sylvestre extract is available as powder 
that presents low flowability due to its small particle size which causes problems in the 
filling of the hard capsules. An evaluation of these excipients was also performed in the 
presence of different lubricants (magnesium stearate or talc). The study showed that 
microcrystalline cellulose is a better diluent than lactose or starch, because it produces the 
most uniform particle size distribution when added to Gymnema sylvestre extract and also 
reduces the percentage of fine particles resulting in acceptable variation of the weight 
among the capsules (RSD< 4%). On the other hand, starch and lactose increase the number 
of small particles that worsen the flowability of the powder mixture. Furthermore, 
microcrystalline cellulose associated with 1% lubricant renders a powder mixture ready for 
encapsulation of Gymnema sylvestre extract in hard gelatin capsules, since flow agents 
optimize the capsule filling in the compounding routine practices [82]. The foregoing 
suggests that microcrystalline cellulose can be an appropriate diluent in formulating similar 
flowable plant extracts. 
3.2.2. Cellulose ether derivatives in sustained/controlled release 
3.2.2.1. Carboxymethylcellulose and hydroxypropylmethylcellulose 
Some studies reveal improper use of cellulosic excipients. For example, using a high 
percentage (30% w/w) of CMC-Na (anionic polymer) as a diluent in the compounding of 
capsules of simvastatin has a deleterious effect. These capsules showed serious drug release 
problems in pharmaceutical tests because they did not disintegrate or dissolve at all [83]. In 
this case, CMC-Na should have been used as a capsule disintegrating agent at a much 
inferior concentration (< 6%) [12]. 
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CMC-Na and HPMC (nonionic polymer) were evaluated by in vitro release studies with 
regards to ibuprofen (non-steroidal anti-inflammatory) extended-release from hard gelatin 
capsules. The study showed that different grades of CMC-Na and HPMC could control 
ibuprofen release to a substantial degree when used as diluents. Furthermore, the molecular 
weight of the polymer group that is directly related to the viscosity grade affects the drug 
release: the higher the molecular weight is, the slower the drug release is [40]. One year 
later, these researchers evaluated ibuprofen bioavailability (healthy volunteers) from hard 
gelatin capsules containing different grades of HPMC (K100 and K15M) and CMC-Na (low, 
medium, high viscosity). These capsules were prepared by filling the shells with the simple 
mixture of the powders (drug and polymer). The study showed that different viscosities of 
HPMC can modify the absorption rate of ibuprofen from hard gelatin capsules, in close 
correlation with a previous in vitro study. In particular, a higher viscosity HPMC (K15M) 
was a better diluent in sustained-release. On the other hand, the use of the CMC-Na with 
different viscosity grades did not allow for the control of the absorption rate of ibuprofen 
and did not correspond to in vitro results. However, none of the polymers seemed to have 
any effect on the bioavailability of the ibuprofen from hard gelatin capsules [39]. 
Slow-release morphine (opioid analgesic used for the relief of pain) capsules 
extemporaneously prepared were investigated regarding their dissolution profile. Three 
batches of capsules prepared by a pharmacist were compared with each other and with 
tablets acquired in the market. The authors describe how similar slow-release profiles were 
found for tablets and compounded capsules, though the latter showed a faster release-rate 
for morphine sulphate. Despite small variations from batch to batch, the authors describe 
that compounded capsules showed a remarkably consistent slow-release profile in in vitro 
studies [34]. 
Another study of compounded capsules containing 300 mg of morphine sulphate (a dosage 
unavailable in the market) reported the use of HPMC in sustained-release. There has been 
considerable controversy about the advisability of this practice. Release studies, performed 
according to the United States Pharmacopeia (USP) using a dissolution apparatus of type III, 
showed that almost half of the morphine was released in the first hour and that the release 
of the remainder was not adequately sustained. As verified in other studies, the increase of 
HPMC prolonged release and reduced drug release in the first hour. Other formulations 
prepared by placing compressed pellets in capsules showed a sustained release significantly 
beyond that of the pellets’ original formulation. Considering that the medication can be 
taken after a meal, the agitation of the gastrointestinal tract would have increased, resulting 
in the reduction of the sustained release period and in a slight increase of the drug amount 
during the first hour after administration. In the first formulation, the capsules did not 
exhibit sustained-release that could be adequate for most applications. Formulations with a 
greater percentage of the HPMC are preferred. Furthermore, the pelleted formulation was 
superior, but it may not be feasible because it is too labour-intensive [35]. 
Slow-release capsules of morphine sulphate (15, 60, 200 mg) and oxycodone hydrochloride 
(10, 80, 200 mg) were evaluated in vitro by USP dissolution apparatus II. All capsules (three 
 
Cellulose and Its Derivatives Use in the Pharmaceutical Compounding Practice 155 
batches of each) were compounded in a local pharmacy employing 40% HPMC (E4M 
Premium CR) and lactose as excipients and a specific machine for capsule-filling. The 
authors observed that the release of the active ingredients from the compounded capsules 
after 0.5, 4 and 12 h were less than 23%, 85% and 98%, demonstrating that HPMC is an 
adequate excipient for preparing slow-release capsules of morphine sulphate and 
oxycodone hydrochloride. The authors recommend that the ratio of active ingredient to 
polymer should remain constant regardless of the capsule size in order to achieve similar 
release rates, provided there is some degree of compression within the capsule shell. In vitro 
performance showed small intra-batch variations as well as inter-batch variations which 
were not statistically significant. Thus the compounding of slow release capsules yielded 
reproducible formulations. However, the authors mention that clinical evaluation is needed 
in order to determine whether the small differences are significant [37]. 
A variety of drugs, especially natural bioidentical hormones, have been exploited in 
compounding using matrix systems since 2002. Hydrophilic matrix systems were mentioned 
as being successfully used in slow-release capsules. The authors report that a good response 
of patients in a dose-related manner was observed in response to all micronized hormones 
administered in slow-release capsules [36]. 
Polymers of HPMC (K100MPRCR, K15MPRCR and E4MCR) in different proportions from 15 
to 35% w/w were also used as extended-release excipients in the compounding of capsules 
containing 100 mg of theophylline. The polymers of HPMC were employed to prepare 
capsules by volumetric method for powder filling in a manual encapsulator. The extended 
drug release was evaluated using USP apparatus I for industrially-produced batches and for 
those obtained by compounding process. The dissolution profile obtained for the higher ratio 
(35% w/w) of HPMC (E4MCR) met USP specifications. Furthermore, reproducibility was 
observed with ten other compounded batches. HPMC was efficient in controlling the release of 
theophylline from the matrix of the capsules prepared by compounding. However, extended-
release capsules containing 100 mg of theophylline (pellets) available in the market did not 
show prolonged release when submitted to the same test conditions [38]. 
To summarize, CMC-Na does not seem to be an adequate slow-releasing agent for 
preparing the capsules regardless of its viscosity. On the other hand, HPMC is a promising 
agent for prolonging the release of drugs, since it has been used before with success. The 
results suggest a relationship between degree of viscosity of HPMC and slow release 
(ibuprofen, morphine). However, reproducibility is an important requisite, and may not be 
assured for all formulations. In addition, studies of therapeutic efficacy are also scarce for 
such compounded products. 
3.2.3. Cellulose ester derivatives in delayed release 
Cellulose ester derivatives are used for enteric coatings of capsules, making them resistant 
to dissolution in low pH environments, such as the stomach, but allowing for their rapid 
disintegration in higher pH environments, such as the intestine. The efficiency of the coating 
is limited by the smooth and nonporous surface of the hard capsules. Studies into anti-
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inflammatory and anti-secretory (H+ pumps inhibitors) drugs, such as diclofenac and 
pantoprazole sodium salts, respectively, show that these drug formulations must be coated 
because they can irritate the stomach walls or degrade in acid environments [84,85]. 
3.2.3.1. Cellulose acetate phthalate 
CAP and other agents (formaldehyde, methacrylic acid copolymer) have been used to 
compound delayed-release capsules of diclofenac using specific small-scale machinery or 
manual immersion in order to evaluate the efficiency of these enteric coating processes [32]. 
Capsules coated with CAP (using acetone as solvent) prepared with either small machinery 
or twofold manual immersion showed adequate gastro-resistance, for which the release of 
the drug was less than 10% in acid and greater than 75% in buffered conditions. However, 
the capsules coated by machinery had a poorer visual aspect than those coated by the 
manual process [32]. In spite of this difference, the authors did not suggest which method 
was the most adequate to compound delayed-release capsules of diclofenac. 
A simple, quick and easily reproducible method for compounding enteric-release capsules 
containing diclofenac has also been described. Twenty-two batches of diclofenac sodium 
capsules (n=60) were divided into three groups, which were submitted to different processes 
of coating. A small-scale machine and an enteric coating by atomization (spraying) of 
organic solutions of polymers (5% CAP in a mix of acetone and alcohol) were employed for 
ten and six batches, respectively. Before coating, the capsules’ hemi receptacles were sealed 
by treatment with 50% v/v hydroalcoholic solution. The dissolution test results were 
statistically compared inter-batch and also with reference commercial product (Voltaren® 
DR). Most of the batches (>75%) met the pharmacopeial requirements for enteric release, in 
both acid (less than 10%) and buffered (greater than 80%) conditions [33]. Results confirmed 
that CAP is an effective enteric coating agent in compounding practice and that the 
application of adequate techniques in pharmacies is important. 
Delayed release capsules obtained by compounding and coating with organic solutions of 
CAP have been evaluated for pro-drug sodium pantoprazole, a proton pump inhibitor that 
undergoes degradation in the acid environment of the stomach [31,84,85]. Quality control 
tests were performed on capsules locally acquired in compounding pharmacies. Dissolution 
studies for gastro-resistance evaluation were performed with granules of pantoprazole 
coated with CAP and encapsulated, as well as with capsules coated with CAP or other 
agents (formaldehyde, shellac, methacrylic acid copolymer). However, all the samples 
prepared by coating with CAP (capsules or granules) released their content in an acid 
environment and did not show adequate gastro-resistance [31]. These results reveal the need 
for suitable coating techniques for compounding gastro-resistant capsules, since CAP is 
admittedly an effective agent for enteric coating. 
4. Conclusion 
Cellulose and its derivatives are very important excipients in compounded medicines. Many 
compounded preparations containing such excipients have been investigated since 1992, 
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especially for extemporaneous use; however, a great effort is still necessary in this field in 
order to assure quality, safety and efficacy for several other drugs. This aspect is even more 
relevant when these products require specific pharmaceutical features (such as delayed 
release) and, consequently, adequate techniques for achieving drug therapy success. It 
points towards the need for more research into ways to properly disseminate the 
appropriate use of cellulose derivatives in compounding pharmacies. A greater attention 
should be paid to this field because compounding is a growing practice in many countries as 
a result of pharmaceutical care that prioritizes the person in his/her individuality, as 
opposed to the average population usually targeted by companies. For all these reasons, 
cellulose derivatives and their applications in compounding practice were reviewed, with 
an emphasis on their use in solid dosage forms with modified release. Addressing the use of 
the cellulose derivatives, such as cellulose acetate phthalate, can be critical in the coating of 
capsules by hand. 
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